Antibiotics Species/Hospital N (%)
K. pneumoniae /A K. oxytoca /A K. pneumoniae/B Total
Amoxicillin + Clavulanic Acid -AMC 2 (25,0) 0 (0,0) 4 (57,1) 6 (28,6)
Nalidixic acid-NAL 2 (25,0) 0 (0,0) 6 (85,7) 8 (38,1)
Amikacin-AMI 1 (12,5) 0 (0,0) 0 (0,0) 1 (4,8)
Amoxicillin-AMO 8 (100,0) 6 (100,0) 7(100,0) 21(100,0)
Ampicillin -AMP 8 (100,0) 6 (100,0) 7(100,0) 21(100,0)
Aztreonam-ATM 2 (25,0) 0 (0,0) 6 (85,7) 8 (38,1)
Cephalothin-CFL 2 (25,0) 0 (0,0) 5 (71,4) 7 (33,3)
Ceftamet-CEF 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0)
Cefotaxime CTX- 2 (25,0) 0 (0,0) 5 (71,4) 7 (33,3)
Ceftazidime-CAZ 0 (0,0) 0 (0,0) 1 (14,3) 1 (4,8)
Chloramphenicol-CLO 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0)
Gentamicin-GEN 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0)
Imipenem-IPM 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0)
Kanamycin-KN 3 (37,5) 0 (0,0) 0 (0,0) 3 (14,3)
Neomycin-NO 2 (25,0) 0 (0,0) 1 (14,3) 3 (14,3)
Sulfaxotrim-SUT 0 (0,0) 0 (0,0) 0 (0,0) 0 (0,0)
Tetracycline-TET 2 (25,0) 0 (0,0) 3 (42,9) 5 (23,8)
Ticarcillin + clavulanic acid-TIC 1 (12,5) 0 (0,0) 0 (0,0) 1 (4,8)
Table 3: Resistance profile shown by Klebsiella isolates to antimicrobial agents for therapeutic use in the hospitals studied